AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Insider Transactions Reported | Ptc Therapeutics(PTCT)saw insider trading activity on 9/11/2025
ByAinvest
Thursday, Sep 11, 2025 6:00 pm ET1min read
Ptc Therapeutics(PTCT) saw insider trading activity on 9/11/2025, there were 2 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 9/11/2025 | -- | SOUTHWELL DAVID P | Buy | 12000 | 30.86 | 370.32k |
| 9/11/2025 | -- | SOUTHWELL DAVID P | Sell | 12000 | 58.34 | 700.08k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Sell | 6017 | 56.91 | 342.43k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Buy | 8528 | 18.01 | 153.59k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Sell | 1238 | 56.85 | 70.38k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Buy | 20411 | 30.86 | 629.88k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Buy | 8423 | 11.23 | 94.59k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Buy | 2488 | 11.32 | 28.16k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Sell | 1250 | 56.86 | 71.08k |
| 9/9/2025 | CHIEF BUSINESS OFFICER | Pauwels Eric | Sell | 14647 | 56.92 | 833.71k |
[Company Profile]
Ptc Therapeutics, Inc. was incorporated as a Delaware corporation on March 31, 1998.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. While the company's discovery programs are directed at targets in multiple therapeutic areas, the company is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. The company leads product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet